Current Neurology and Neuroscience Reports

, Volume 12, Issue 6, pp 655–665 | Cite as

Tetanus in Ethiopia: Unveiling the Blight of an Entirely Vaccine-Preventable Disease

Infection (B Jubelt, Section Editor)


Today, tetanus exacts its toll only in resource-poor countries like Ethiopia. Agrarian rural life with limited vaccine typifies tetanus risk in Ethiopia where current tetanus control trends on expanding infant immunization and eliminating highly prevalent maternal and neonatal tetanus (MNT). Protection by infant tetanus immunization primers disappears within an average of 3 years, if not followed by boosters. Second-year of life, school-based, and universal 10-yearly tetanus immunizations need to be supplemented. Facility-based reviews in Ethiopia reveal a continued burden of tetanus at tertiary-level hospitals where ICU care is suboptimal. Quality of medical care for tetanus is low - reflected by high case-fatality-rates. Opportunities at primary-health-care-units (antenatal-care, family planning, abortion, wound-care, tetanus-survivors) need to be fully-utilized to expand tetanus immunization. Prompt wound-care with post-exposure prophylaxis and proper footwear must be promoted. Standard ICU care needs to exist. Realization of cold-chain-flexible, needle-less and mono-dose vaccine programs allow avoiding boosters, vaccine-refrigeration, and improve compliance.


Tetanus Ethiopia Tetanus vaccination Maternal and neonatal tetanus 


Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    GNI per capita, PPP (current international $). Available at: Accessed June 16, 2012.
  2. 2.
    •• Central Statisitcal Agency, A.A., Ethiopia, Ethiopia Demographic and Health Survey, 2012. This report provides the most recent and the largest community-based data summary on immunization and related indicators in Ethiopia. It gives a comprehensive review of health and demographic indicators that can be accessed by multitude of sectors. Google Scholar
  3. 3.
    WHO, The global burden of disease. 2004; update, 2008.Google Scholar
  4. 4.
    •• Amare A, Melkamu Y, Mekonnen D. Tetanus in adults: clinical presentation, treatment and predictors of mortality in a tertiary hospital in Ethiopia. J Neurol Sci. 2012;317:62–5. This recent study provides a retrospective analysis of 68 tetanus patients admitted from 2001–2009 to the highest referral specialized hospital in Ethiopia - the Black Lion Hospital. It has a comprehensive description of clinical forms of disease, treatment modalities, rates, and predictors of fatality, and relevant recommendations. PubMedCrossRefGoogle Scholar
  5. 5.
    Tadesse H, Deribew A, Woldie M. Predictors of defaulting from completion of child immunization in south Ethiopia, May 2008–a case control study. BMC Publ Health. 2009;9:150.CrossRefGoogle Scholar
  6. 6.
    Woldeamanuel YW, Hassan A. Tetanus weighs on neurological burden in Ethiopia. World Neurol. 2010;25:14.Google Scholar
  7. 7.
    Amare A, Yami A. Case-fatality of adult Tetanus at Jimma University Teaching Hospital, Southwest Ethiopia. Afr Health Sci. 2011;11:36–40.PubMedGoogle Scholar
  8. 8.
    Worku T, Bayou A, Aseffa A. Tetanus in a rural hospital in Northeast Ethiopia. Ethiopian J Health Dev. 2004;18:55–6.Google Scholar
  9. 9.
    Amsalu S, Lulseged S. Tetanus in a children's hospital in Addis Ababa: review of 113 cases. Ethiopia Med J. 2005;43:233–40.Google Scholar
  10. 10.
    Hodes RM, Teferedegne B. Tetanus in Ethiopia: analysis of 55 cases from Addis Ababa. East Afr Med J. 1990;67:887–93.PubMedGoogle Scholar
  11. 11.
    Nida H. Neonatal tetanus in Awassa: retrospective analysis of patients admitted over 5 years. Ethiopia Med J. 2001;39:241–6.Google Scholar
  12. 12.
    Ogunrin O. Tetanus–a review of current concepts in management. J Postgrad Med. 2009;11:46–61.Google Scholar
  13. 13.
    Atkinson W, Wolfe C, Hamborsk J, editors. Tetanus, in epidemiology and prevention of vaccine-preventable diseases. Washington: Public Health Foundation; 2011. p. 291–300.Google Scholar
  14. 14.
    Cherry J, Harrison R. Tetanus. In: Feigin RD, Cherry J, Demmler-Harrison GJ, Kaplan SL, editors. Textbook of pediatric infectious diseases. Philadelphia: Elsevier; 2004. p. 1766–76.Google Scholar
  15. 15.
    Bleck T. Clostridium tetani. In: Mandell GL, Bennett JE, Dolin R, editors. Bennett's principles and practice of infectious diseases. Philadelphia: Churchill Livingstone; 1995. 9-p. 2373–8.Google Scholar
  16. 16.
    Alene G. Harmful traditional health practices: a cross-sectional survey among under-five children in Dembia district, north-west Ethiopia. Ethiopia J Health Biomed Sci. 2010;2:83–93.Google Scholar
  17. 17.
    WHO. Podoconiosis: endemic non-filarial elephantiasis. 2012 (cited 2012 29/05/12).Google Scholar
  18. 18.
    Simmonsen O, Block A, Heron I. Epidemiology of tetanus in Denmark 1920–1982. Scand J Infect Dis. 1987;19:437–44.CrossRefGoogle Scholar
  19. 19.
    Roper M, Vandelaer J, Gasse F. Maternal and neonatal tetanus. Lancet. 2007;370:1947–59.PubMedCrossRefGoogle Scholar
  20. 20.
    WHO. Immunization profile - Ethiopia 2012. Available at: Accessed June 16, 2012.
  21. 21.
    Poverty Reduction and Immunizations. Considering immunizations in the context of debt relief for poor countries. Prepared for: the Bill & Melinda Gates Children’s Vaccine Program at PATH, 2000: Bethesda, Maryland. Available at: Accessed June 16, 2012.
  22. 22.
    Outsourcing the vaccine supply chain and logistics system to the private sector: the Western Cape Experience in South Africa.PATH, World Health Organization. 2011;Seattle:PATH. 2011. Available at: Accessed June 16, 2012.
  23. 23.
    Temperature sensitivity of vaccines. Immunization, vaccines and biologicals. World Health Organization. 2006: Geneva, Switzerland. Available at: Accessed June 16, 2012.
  24. 24.
    Health and Health Related Indicators, 2009/10. Federal Ministry of Health - Ethiopia, Ethiopian Calendar 2002. Available at: Accessed June 16, 2012.
  25. 25.
    Kidane T, Yigzaw A, Sahilemariam Y, Bulto T, Mengistu H, Belay T, et al. National EPI coverage survey report in Ethiopia, 2006. Ethiopia J Health Dev. 2008;22:148–57.Google Scholar
  26. 26.
    Using immunization coverage rates for monitoring health sector performance: measurement and interpretation issues. HNP Discussion Series. Bose and Batson A. Health, nutrition, population discussion paper, August 2000: Washington, DC. Available at: Accessed June 16, 2012.
  27. 27.
    Immunization surveillance, assessment and monitoring. Maternal and Neonatal Tetanus (MNT) elimination. Progress towards global MNT elimination. World Health Organization. January 2012. Available at: Accessed June 16, 2012.
  28. 28.
    UNICEF- Ethiopia. Immunization plus. Polio, measles and MNTE activities. Avaliable at: Accessed June 16, 2012.
  29. 29.
    Investing in boys and girls in Ethiopia. Past, present and future, UNICEF-Ethiopia and Ministry of Finance and Economic Development, 2012. Available at: Accessed June 16, 2012.
  30. 30.
    Using early childhood booster doses to maintain the elimination of Neonatal Tetanus. Steinglass R. Based on a paper delivered at the World Health Organization (WHO) Neonatal Tetanus Elimination Technical Consultation, Geneva, 1997. Available at: Accessed June 16, 2012.
  31. 31.
    Galazka A. The immunological basis for immunization. Module 3: tetanus. Global programme for vaccines and immunization. Geneva: Expanded Programme on Immunization; 1996.Google Scholar
  32. 32.
    Naimoli JF, Challa S, Schneidman M, Kostermans K. Toward a grounded theory of why some immunization programs in sub-Saharan Africa are more successful than others: a descriptive and exploratory assessment in 6 countries. Health Policy Plann. 2008:23:379–89.Google Scholar
  33. 33.
    England S. “The evidence base for interventions to reduce mortality from vaccine-preventable diseases in low and middle-income Countries” (Geneva: Commission on Macroeconomics and Health, Working Paper Series, June 5, 2001) 2001.Google Scholar
  34. 34.
    Bloom D, Canning D, Weston M. The value of vaccination. World Econ. 2004;6:15–39.Google Scholar
  35. 35.
    Miguel E, Kremer M. Worms: identifying impacts on education and health the presence of treatment externalities. Econometrica. 2004;72:159–217.CrossRefGoogle Scholar
  36. 36.
    Bawah AA, Phillips JF, Adjuik M, Vaughan-Smith M, Macleod B, Binka FN. The impact of immunization on the association between poverty and child survival: evidence from Kassena-Nankana District of northern Ghana. Scand J Publ Health. 2010;38:95–103.Google Scholar
  37. 37.
    Mekonen Y. Missed opportunity of tetanus toxoid immunization among pregnant women in Southern Ethiopia. Ethiopian J Health Dev. 2000;14:143–8.Google Scholar
  38. 38.
    WHO. Tetanus vaccine: WHO position paper. Wkly Epidemiol Rec. 2006;81:198–208.Google Scholar
  39. 39.
    CDC, Recommended immunization schedules for persons aged 0 through 18 years, United States 2012. Available at: Accessed June 16, 2012.
  40. 40.
    Maru M, Getahun A, Hosana S. A house-to-house survey of neonatal tetanus in urban and rural areas in the Gondar region, Ethiopia. Trop Geogr Med. 1988;40:233–6.PubMedGoogle Scholar
  41. 41.
    UNICEF-Ethiopia. Maternal and neonatal tetanus. 2004. Available at: Accessed June 16, 2012.
  42. 42.
    Kidane T. Factors influencing TT immunization coverage and protection at birth coverage in Tselemi District, Ethiopia. Ethiopia J Health Dev. 2004;18:153–8.Google Scholar
  43. 43.
    Steinglass R. Eliminating neonatal tetanus, excerpted from basic support for institutionalizing child survival project (BASICS II) for the United States Agency for International Development. Arlington, Virginia, June 2001.Google Scholar
  44. 44.
    Ramos JM, Reyes F, Tesfamariam A. Tetanus in a rural Ethiopian hospital. Trop Doct. 2008;38:104–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Habte-Gabr E, Mengistu M. Tetanus in Gondar Public Health College Hospital, Ethiopia: a review of 72 cases. Ethiopia Med J. 1978;16:53–61.Google Scholar
  46. 46.
    Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet (online). 2010;375:1969–87.CrossRefGoogle Scholar
  47. 47.
    UNICEF, Maternal and neonatal tetanus elimination initiative. Pampers UNICEF 2010 campaign launch. Available at: Accessed June 16, 2012.
  48. 48.
    Stanfield J, Galazka A. Neonatal tetanus in the world today. Bull World Health Organ. 1984;62:647–69.PubMedGoogle Scholar
  49. 49.
    Meegan ME, Conroy RM, Lengeny SO, Renhault K, Nyangole J. Effect on neonatal tetanus mortality after a culturally-based health promotion programme. Lancet. 2001;358:640–1.PubMedCrossRefGoogle Scholar
  50. 50.
    Vandelaer J, Birmingham M, Gasse F, Kurian M, Shaw C, Garnier S. Tetanus in developing countries: an update on the maternal and neonatal tetanus elimination initiative. Vaccine. 2003;21:3442–5.Google Scholar
  51. 51.
    Brenzel L, Wolfson LJ, Fox-Rushby J, Miller M, Halsey NA. Vaccine-preventable disease. In: Jamison D, Breman J, Measham J, editors. Disease control priorities in developing countries. New York: Oxford University Press; 2006. p. 389–411.Google Scholar
  52. 52.
    Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne G, Claeson M, et al. Advancement of global health: key messages from the Disease Control Priorities Project. Lancet. 2006;367:1193–208.PubMedCrossRefGoogle Scholar
  53. 53.
    Ehreth J. The global value of vaccination. Vaccine. 2003;21:596–600.PubMedCrossRefGoogle Scholar
  54. 54.
    UNICEF. Maternal and neonatal elimination by 2005. Strategies for achieving and maintaining elimination. 2000. Available at: Accessed June 16, 2012.
  55. 55.
    United Nations Millenium Development Goals. A gateway to the UN system's work on the MDGs. Available at: Accessed June 16, 2012.
  56. 56.
    Pascual FB, McGinley EL, Zanardi LR, Cortese MM, Murphy TV. Tetanus surveillance - United States. MMWR Surveill Summ. 2003;52:1–8.PubMedGoogle Scholar
  57. 57.
    Wassila S, et al. Tetanus toxoid. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. Philadelphia: Saunders; 2008. p. 805–39.Google Scholar
  58. 58.
    Deressa W, Ali A. Malaria-related perceptions and practices of women with children under the age of five years in rural Ethiopia. BMC Publ Health. 2009;9:259.Google Scholar
  59. 59.
    Hadgu P, Tsega E, Geremew S. Tetanus: review of the literature and outline of prophylaxis and management. Ethiopia Med J. 1975;1:161–70.Google Scholar
  60. 60.
    Brabin BJ, Nagel J, Hagenaars AM, Ruitenberg E, van Tilborgh AM. The influence of malaria and gestation on the immune response to one and two doses of adsorbed tetanus toxoid in pregnancy. Bull, Geneva, World Health Organ. 1984;62:919–30.Google Scholar
  61. 61.
    Ethiopian Aids Resource Center. National factsheet 2010. AIDS in Ethiopia main indicators 2010. Available at: Accessed June 16, 2012.
  62. 62.
    WHO, Immunization policy, global programme for vaccines and immunization 1996: Geneva, Switzerland. Available at: Accessed June 16, 2012.
  63. 63.
    Blanche S, Le Deist F, Fischer A, Veber F, Debre M, Chamaret S, et al. Longitudinal study of 18 children with perinatal LAV/HTLV infection: attempt at prognostic evaluation. J Pediatr. 1986;109:965–70.Google Scholar
  64. 64.
    Kurtzhals JA, Kjeldsen K, Heron I, Skinhøj P. Immunity against diphtheria and tetanus in human immunodeficiency virus -infected Danish men born 1950–1959. APMIS. 1992;100:803–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Kroon F. Immunoglobulin (IgG) subclass distribution and IgG1 avidity of antibodies in human immunodeficiency virus-infected individuals after revaccination with tetanus toxoid. Clin Diagn Lab Immunol. 1999;6:352–5.PubMedGoogle Scholar
  66. 66.
    Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bulletin, Geneva, World Health. Organization. 2003;81:6170.Google Scholar
  67. 67.
    de Moraes-Pinto MI, Almeida AC, Kenj G, Filgueiras TE, Tobias W, Santos AM, et al. Placental transfer and maternally acquired neonatal IgG immunity in human immunodeficiency virus infection. J Infect Dis. 1996;173:1077–84.Google Scholar
  68. 68.
    Okoko J, Wesumperuma H, Hart C. The influence of prematurity and low birthweight on transplacental antibody transfer in a rural west African population. Trop Med Int Health. 2001;6:529–34.PubMedCrossRefGoogle Scholar
  69. 69.
    de Moraes-Pinto MI, Verhoeff F, Chimsuku L, Milligan PJ, Wesumperuma L, Broadhead RL, et al. Placental antibody transfer: influence of maternal HIV infection and placental malaria. Arch Dis Child Fetal Neonatal Ed. 1998;79:202–5.Google Scholar
  70. 70.
    Okoko BJ, Wesuperuma LH, Ota MO, Banya WA, Pinder M, Gomez FS, et al. Influence of palcental malaria infection and maternal hypergammaglobulinema on materno-foetal transfer of measles and tetanus antibodies in a rural west African population. J Health Popul Nutr. 2001;19:59–65.Google Scholar
  71. 71.
    FMOH-Ethiopia, Tuberculosis, Leprosy and TB/HIV prevention and control programme, 2008. Addis Ababa.Available at: Accessed June 16, 2012.
  72. 72.
    Hodes R, Teferedegne B. Tetanus in leprosy patients: report of five cases. Int J Lepr Other Mycobact Dis. 1988;56:228–30.PubMedGoogle Scholar
  73. 73.
    Singh M, Kumar B, Ayagiri A, Kaur S. Natural tetanus immunity in lepromatous leprosy patients. Indian J Lepr. 1986;58:91–5.PubMedGoogle Scholar
  74. 74.
    Dharmendra SH. Leprosy. Bombay: Kothari Publishing House; 1978. p. I.Google Scholar
  75. 75.
    Goodwin D, Wood M. Bacteria isolated from plantar ulcers of Ethiopian leprosy patients with antibacterial drug sensitivities of the isolates. Trans R Soc Trop Med Hyg. 1970;64:421–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Guilfoile P. Deadly diseases and epidemics: tetanus. In: Babock H, editor. Deadly diseases and epidemics. New York: Infobase Publishing; 2008. p. 100.Google Scholar
  77. 77.
    Berger SA, Cherubin CE, Nelson S, Levine L. Tetanus despite preexisting antitetanus antibody. JAMA. 1978;240:769–70.PubMedCrossRefGoogle Scholar
  78. 78.
    Goulon M, Girard O, Grosbuis S, Desormeau JP, Capponi MF. [Les anticorps antitetaniques. Titrage avant seroanatoxiono-therapie chez 64 tetaniques]. Nouv Presse Med. 1972;1:3049–50.PubMedGoogle Scholar
  79. 79.
    Passen E, Andersen B. Clinical tetanus despite a “protective” level of toxin-neutralizing antibody. JAMA. 1986;255:1171–3.PubMedCrossRefGoogle Scholar
  80. 80.
    Matzkin H, Regev S. Naturally acquired immunity to tetanus in an isolated community. Infect Immun. 1985;48:267–8.PubMedGoogle Scholar
  81. 81.
    Ray SN, Ray K, Grover SS, Sharma RS, Sharma SP. Sero-survey of diphtheria and tetanus antitoxin. Indian J Med Res. 1978;68:901–4.PubMedGoogle Scholar
  82. 82.
    Veronesi R, Cecin H, Corrêa A, Tavares J, Moraes C, Bertoldo OJ. New concepts in tetanus immunization: naturally acquired immunity. J Hyg Epidemiol Microbiol Immunol. 1975;19:126–34.Google Scholar
  83. 83.
    Veronesi R, Bizzini B, Focaccia R, Coscina AL, Mazza CC, Focaccia MT, et al. Naturally acquired antibodies to tetanus toxin in humans and animals from Galapagos Islands. J Infect Dis. 1983;147:308–11.Google Scholar
  84. 84.
    Dastur FD, Awatramani VP, Dixit SK, D'Sa JA, Cooverji ND, Anand MP. Response to single dose of tetanus vaccine in subjects with naturally acquired tetanus antitoxin. Lancet. 1981;2:219–22.Google Scholar
  85. 85.
    MacLennan R, Schofield FD, Pittman M, Hardegree MC, Barile MF. Immunization against neonatal tetanus in New Guinea: antitoxin response of pregnant women to adjuvant and plain toxoids. Bull, Geneva, World Health Organ. 1965;32:683–97.Google Scholar
  86. 86.
    Breman JG, Wright GG, Levine L, Latham WC, Compaoré KP. The primary serological response to a single dose of adsorbed tetanus toxoid, high concentration type. Bull, Geneva, World Health Organ. 1981;59:745–52.Google Scholar
  87. 87.
    Menon PS, Sahai G, Joshi VB, Murthy RG, Boparai MS, Thomas AK. Field trial on frozen and thawed tetanus toxoid. Indian J Med Res. 1976;64:25–32.Google Scholar
  88. 88.
    Borrow R, Balmer P, Roper M. The immunological basis for immunization series. Module 3: tetanus. Geneva, Switzerland: WHO Document Production Services. 2006.Google Scholar
  89. 89.
    Trujillo MH, Castillo A, España J, Manzo A, Zerpa R. Impact of intensive care management on prognosis of tetanus: analysis of 641 cases. Chest. 1987;92:63–5.PubMedCrossRefGoogle Scholar
  90. 90.
    Melaku Z, Alemayehu M, Oli K, Tizazu G. Pattern of admissions to the medical intensive care unit of Addis Ababa University Teaching Hospital. Ethiopia Med J. 2006;44:33–42.Google Scholar
  91. 91.
    Afshar M, Raju M, Ansell D, Bleck TP. Narrative review: tetanus-a health threat after natural disasters in developing countries. Ann Intern Med. 2011;154:329–35.PubMedGoogle Scholar
  92. 92.
    Shibuya M, Sugimoto H, Sugimoto T, Shimazu T, Uenishi M, Yoshioka T. The use of continuous spinal anesthesia in severe tetanus with autonomic disturbance. J Trauma. 1989;29:1423–9.Google Scholar
  93. 93.
    Vassa NT, Doshi HV, Yajnik VH, Shah SS, Joshi KR, Patel SH. Comparative clinical trial of diazepam with other conventional drugs in tetanus. Postgrad Med J. 1974;50:755–8.Google Scholar
  94. 94.
    Saissy JM, Demazière J, Vitris M, Seck M, Marcoux L, Gaye M, et al. Treatment of severe tetanus by intrathecal injections of baclofen without artificial ventilation. Intensive Care Med. 1992;18:241–4.Google Scholar
  95. 95.
    Engrand N, Guerot E, Rouamba A, Vilain G. The efficacy of intrathecal baclofen in severe tetanus. Anesthesiology. 1999;90:1773–6.PubMedCrossRefGoogle Scholar
  96. 96.
    Salimpour R. Tetanus of the newborn in Tehran. A ten year study of 880 cases. J Trop Pediatr Environ Child Health. 1978;24:140–2.PubMedGoogle Scholar
  97. 97.
    Ertem M, Cakmak A, Saka G, Ceylan A. Neonatal tetanus in the South-Eastern region of Turkey: changes in prognostic aspects by better health care. J Trop Pediatr Environ Child Health. 2004;50:297–300.Google Scholar
  98. 98.
    Thwaites CL, Yen LM, Loan HT, Thuy TT, Thwaites GE, Stepniewska K, et al. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet. 2006;368:1436–43.Google Scholar
  99. 99.
    King W, Cave D. Use of esmolol to control autonomic instability of tetanus. Am J Med. 1991;91:425–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Sutton DN, Tremlett MR, Woodcock TE, Nielsen MS. Management of autonomic dysfunction in severe tetanus: the use of magnesium sulphate and clonidine. Intensive Care Med. 1990;16:75–80.PubMedCrossRefGoogle Scholar
  101. 101.
    Buchanan N, Cane RD, Wolfson G, De Andrade M. Autonomic dysfunction in tetanus: the effects of a variety of therapeutic agents, with special reference to morphine. Intensive Care Med. 1979;5:65–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Kerr JH. Insensible fluid losses in severe tetanus. Intensive Care Med. 1981;7:209–12.PubMedCrossRefGoogle Scholar
  103. 103.
    Wright DK, Lalloo UG, Nayiager S, Govender P. Autonomic nervous system dysfunction in severe tetanus: current perspectives. Crit Care Med. 1989;17:371–5.PubMedCrossRefGoogle Scholar
  104. 104.
    Buchanan N, Smit L, Cane RD, De Andrade M. Sympathetic overactivity in tetanus: fatality associated with propanolol. BMJ. 1978;2:254–5.PubMedCrossRefGoogle Scholar
  105. 105.
    Joshi S, Agrawal B, Malla G, Karmacharya B. Complete elimination of tetanus is still elusive in developing countries: a review of adult tetanus cases from referral hospital in Eastern Nepal. Kathmandu Univ Med J (KUMJ). 2007;5:378–81.Google Scholar
  106. 106.
    Gibson K, Bonaventure Uwineza J, Kiviri W, Parlow J. Tetanus in developing countries: a case series and review. Can J Anaesth. 2009;56:307–15.PubMedCrossRefGoogle Scholar
  107. 107.
    Handel J, McCallum D. A different form of nutrition delivery. Hosp Update. 1995;21:270–7.Google Scholar
  108. 108.
    Cook TM, Protheroe RT, Handel JM. Tetanus: a review of the literature. Br J Anaesth. 2001;87:477–87.Google Scholar
  109. 109.
    Griggs WM, Worthley LI, Gilligan JE, Thomas PD, Myburg JA. A simple percutaneous tracheostomy technique. Surg Gynae Obs. 1990;170:543–5.Google Scholar
  110. 110.
    Singh S, Fetters T, Gebreselassie H, Abdella A, Gebrehiwot Y, Kumbi S, et al. The estimated incidence of induced abortion in Ethiopia. Int Perspect Sex Reproduct Health. 2010;36:16–25.Google Scholar
  111. 111.
    Gebreselassie H, Fetters T, Singh S, Abdella A, Gebrehiwot Y, Tesfaye S, et al. Caring for women with abortion complications in Ethiopia: national estimates and future implications. Int Perspect Sex Reproduct Health. 2010;36:6–15.Google Scholar
  112. 112.
    Brabin L, Kemp J, Maxwell SM, Ikimalo J, Obunge OK, Briggs ND. Protecting adolescent girls against tetanus. BMJ. 1995;311:73–4.PubMedCrossRefGoogle Scholar
  113. 113.
    Shi Z, Zeng M, Yang G, Siegel F, Cain LJ, van Kampen KR, et al. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol. 2001;75:11474–82.Google Scholar
  114. 114.
    Elkharrat D, Espinoza P, De la Coussaye J, Potel G, Pourriat JL, Sanson-Le Pors MJ. [Inclusion of a rapid test in the current Health Ministry Guidelines with the purpose of improving anti-tetanus prophylaxis prescribed to wounded patients presenting at French Emergency Departments]. (Article in French). Med Mal Infect. 2005;35:323–8.Google Scholar
  115. 115.
    Hashem FM, Fahmy SA, El-Sayed AM, Al-Sawahli MM. Development and evaluation of chitosan microspheres for tetanus, diphtheria and divalent vaccines: a comparative study of subcutaneous and intranasal administration in mice. Pharm Dev Technol. 2011. doi:10.3109/10837450.2011.618949
  116. 116.
    Baxendale A, van Hooff P, Durrant LG, Spendlove I, Howdle SM, Woods HM, et al. Single shot tetanus vaccine manufactured by a supercritical fluid encapsulation technology. Int J Pharm. 2011;413:147–54.Google Scholar
  117. 117.
    Merhai Z, Kumar A. Tetanus in infancy and childhood (a review of 110 cases from Addis Ababa, Ethiopia). East Afr Med J. 1986;63:736–41.PubMedGoogle Scholar
  118. 118.
    George AO, Ogunbiyi AO, Amanor-Boadu S, Oluwole OA, Kumuyi O. Tetanus in Nigeria: the economic burden. Trop Doct. 2005;35:126–7.PubMedCrossRefGoogle Scholar
  119. 119.
    Health statistics and health information systems. Metrics: Disability-Adjusted Life Year (DALY) Quantifying the burden of disease from mortality and morbidity. Available at: Accessed August 29, 2012.
  120. 120.
    GNI, PPP (current international $) Available at: Accessed August 29, 2012.

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Anaesthetics, Pain Medicine and Intensive CareChelsea and Westminster Hospital, Imperial College LondonLondonUK
  2. 2.Department of NeurologyAddis Ababa UniversityAddis AbabaEthiopia

Personalised recommendations